In recent years efficacy of small molecule inhibitors of Chk1 has been tested in combination with DNA damaging agents in clinical trials against solid tumors, myeloid leukemia and small cell lung carcinoma with some favorable outcomes [31,32,33,34]. This evidence concerns the gene CHEK1 and myeloid leukemia.